Capsule Summaries

Share

Program Content

Activities

TB Prevention With 3HP vs 6H
3-Mo Rifapentine and Isoniazid vs 6-Mo Isoniazid TB Preventive Therapy in People Living With HIV in Western Kenya
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2025

Expires: September 11, 2025

MK8591A052 Phase III Trial of DOR and ISL
MK-8591A-052: Phase III Trial of Switch From BIC/FTC/TAF to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 12, 2025

Expires: September 11, 2025

MK8591A051
MK-8591A-051: Phase III Trial of Switch From Standard-of-Care ART to DOR/ISL in People Living With Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

CARES 96 Wk
CARES: 96-Wk Efficacy and Safety of LA CAB + RPV in Sub-Saharan Africa
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

PILLAR
PILLAR: Efficacy and Persistence of Long-Acting Cabotegravir in Real-world Phase IV Trial of HIV PrEP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 13, 2025

Expires: September 12, 2025

PURPOSE 1 Adolescent Women
PURPOSE 1: Lenacapavir PrEP in Adolescent Cisgender Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

Lenacapavir, Teropavimab, and Zinlirvimab
Phase II Study Results of Lenacapavir, Teropavimab, and Zinlirvimab for People Living with Virologically Suppressed HIV
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

On Demand PrEP for Women
Utilizing PK/PD Modeling to Optimize On-Demand TDF/FTC PrEP Dosing for Women
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

DoxyPEP for STI Prevention
Doxycycline Postexposure Prophylaxis for STI Prevention in People on HIV PrEP Presenting for Sexual Health Visits
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 14, 2025

Expires: September 13, 2025

STOMP Tecovirimat
Phase III STOMP: Tecovirimat for the Treatment of Clade II Mpox
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

HPTN 094
HPTN 094: Mobile Unit Services Plus Peer Health Navigation vs Peer Health Navigation Alone for People Who Inject Drugs
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

BEe HIVe
BEe-HIVe: HepB-CpG HBV Vaccine Durability in People Living With HIV on ART ± Prior Vaccine History
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

HPTN 084 OLE
HPTN 084 OLE: HIV-1 RNA Screening in Women Receiving Long-Acting Cabotegravir for PrEP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

Semaglutide in HIV
Semaglutide in People Living With HIV: Effect on Cognitive Function
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 17, 2025

Expires: September 16, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare